Acer Therapeutics

Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s product candidates are believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA.

Acumen Executive Search

Building a winning team is critical. Acumen earns your trust and respect by strategizing with you to grow your business. Utilizing our management consultative approach to recruiting, we develop a thorough understanding of your organization’s needs and culture, enabling us to source qualified candidates, that are “the right fit.” Each search is unique and customized. Call to set up a meeting, or email us for our TOP 10 BEHAVIOR INTERVIEW questions – we would love to talk with you!

APDM

APDM’s mission is to develop and commercialize best-in-class solutions for quantifying human movement with wearable technologies. As a first step in this mission, we created the world’s most advanced movement monitors. These range from our premier Opals to our low-cost Sapphires. All of our movement monitors have a full kinematic sensor suite including low-noise triaxial accelerometers, gyroscopes, and magnetometers. To expand on our mission, we developed the first wearable sensor-based gait and balance assessment system, Mobility Lab. This system has […]

Apical

Apical LLC is an Ag-tech Company that combines modern analytical methods, eco-friendly growing products and smart data management techniques to provide growers with the tools they need to grow extremely healthy, optimal yielding crops organically with minimal pest problems.

Aronora

Aronora is a translational biotechnology company engaged in the early-stage commercial development of proprietary biologic therapeutics, including recombinant monoclonal antibodies and enzymes.  Building on the company’s ground-breaking rational approaches to superior drug safety, Aronora’s product candidates have the potential to become first-in-class medical emergency therapeutics to treat life-threatening acute thrombotic vascular diseases early, in the field, even before the patient is hospitalized and the diagnosis is verified.

Bates Medical Systems

Bates Medical Systems LLC (BMS) is developing innovative and cost effective new technology for the detection and diagnosis of breast cancer, one of the leading causes of death among women. BMS’s Automated Breast Ultrasound System (ABUS) provides a pre-operative, non-ionizing radiation evaluation of the breast to accurately identify tumor size and location without compression.

Beaverton, City of

The City of Beaverton is located seven miles west of Portland, Oregon, in the Tualatin River Valley, encompasses 19.6 square miles, and is home to more than 94,000 residents. The city is Oregon’s sixth largest city and the second-largest incorporated city in Washington County.

Biomed

Biomed Diagnostics Inc.

Biomed Diagnostics Inc. is an innovative manufacturer of microbiology diagnostic devices that save money and time, improve workflow and throughput, and reduce sample exposure and contamination.

By combining sample collection, transport and culture in a single platform, the Biomed point-of-care InPouchtm and InTraytmdevices help medical professionals, veterinarians, research teams, environmental and industry scientists worldwide accurately detect, identify, enumerate and differentiate pathogens and non-pathogens.

Blaze Bioscience

Blaze Bioscience is focused on the development of Tumor Paint technology, which is designed to provide real-time, high-resolution visualization of cancer cells during surgery, enabling more precise, complete resection of cancer while sparing normal adjacent tissue. Our lead product—Tumor Paint: BLZ-100—has been shown to illuminate tumors in brain, breast and skin cancers with data demonstrating strong predictive value. The pivotal Phase 2/3 clinical study has been initiated in brain cancer.